{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:48:49Z","timestamp":1785786529115,"version":"3.56.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Diabetes mellitus, particularly type 2 diabetes, is a growing health concern in low- and middle-income countries (LMICs). The potential impact of newer diabetes medications, such as glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT-2) inhibitors, on insulin dosage and health outcomes in these settings is not well understood.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>We developed a microsimulation model to estimate the impact of treating patients with type 2 diabetes who use insulin with GLP-1 receptor agonists or SGLT-2 inhibitors in LMICs. The model utilized data from the Global Health and Population Project on Access to Care for Cardiometabolic Diseases (HPACC) dataset, encompassing surveys from 79 countries and clinical trial data to estimate insulin dose reduction. We incorporated weight-based insulin dosing formulas and hazard ratios for severe hypoglycemia, cardiovascular and renal outcomes, side effects of new therapies, and mortality. The primary outcome was the change in insulin dosage, and secondary outcomes were disability-adjusted life years (DALYs) lost per 1,000 person-years by diabetes complication (micro- and macro-vascular).<\/jats:p>\n<jats:p>Our results indicate that the addition of GLP-1 receptor agonists or SGLT-2 inhibitors could reduce insulin dosage by 8.2 IU\/day (IQR: 6.9, 9.5) and 5.3 IU\/day (IQR: 4.5, 6.2), respectively. The median DALYs lost per 1,000 person-years decreased from 2.20 (IQR: 1.49, 4.02) to 1.01 (IQR: 0.61, 1.86) with GLP-1 receptor agonists and 1.25 (IQR: 0.81, 2.29) with SGLT-2 inhibitors. Primary benefits arose from weight loss, decreased cardiorenal disease, and decreased mortality, with smaller DALY benefits from the prevention of severe hypoglycemia. Key limitations include the inability to differentiate between type 1 and type 2 diabetes in some datasets and reliance on assumptions from clinical trials conducted primarily in high-income countries.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The introduction of GLP-1 receptor agonists and SGLT-2 inhibitors for managing type 2 diabetes in LMICs could significantly reduce insulin dosage and associated health risks, leading to improved outcomes and reduced disability. These findings suggest that expanding access to these newer diabetes medications in LMICs could have substantial public health benefits.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004559","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T17:24:44Z","timestamp":1744910684000},"page":"e1004559","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reduced insulin use and diabetes complications upon introduction of SGLT-2 inhibitors and GLP1-receptor agonists in low- and middle-income countries: A microsimulation"],"prefix":"10.1371","volume":"22","author":[{"name":"Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"pmed.1004559.ref001","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"H Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"pmed.1004559.ref002","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41574-021-00621-y","article-title":"Global accessibility of therapeutics for diabetes mellitus","volume":"18","author":"M Fralick","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"pmed.1004559.ref003","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/1570161117666190405165911","article-title":"The growing epidemic of diabetes mellitus","volume":"18","author":"D Lovic","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"pmed.1004559.ref004","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.diabres.2017.05.004","article-title":"Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes","volume":"130","author":"K Khunti","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"issue":"25","key":"pmed.1004559.ref005","first-page":"2982","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"GA Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10225","key":"pmed.1004559.ref006","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"pmed.1004559.ref007","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejim.2021.11.008","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: a treatment approach far beyond their glucose-lowering effect","volume":"96","author":"R G\u00f3mez-Huelgas","year":"2022","journal-title":"Eur J Intern Med"},{"key":"pmed.1004559.ref008","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"SC Palmer","year":"2021","journal-title":"BMJ"},{"key":"pmed.1004559.ref009","first-page":"766","article-title":"Chronic kidney disease and risk management: cardiovascular risk reduction by SGLT-2 inhibition in type 2 diabetes","volume":"9","author":"S Palmer","year":"2021","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"6","key":"pmed.1004559.ref010","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"HW Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"pmed.1004559.ref011","doi-asserted-by":"crossref","first-page":"e243474","DOI":"10.1001\/jamanetworkopen.2024.3474","article-title":"Estimated sustainable cost-based prices for diabetes medicines","volume":"7","author":"MJ Barber","year":"2024","journal-title":"JAMA Netw Open"},{"key":"pmed.1004559.ref012","article-title":"IDF and the Medicines Patent Pool welcome inclusion of SGLT2 inhibitors to the WHO Essential Medicines List","author":"International Diabetes Federation","year":"2024"},{"key":"pmed.1004559.ref013","article-title":"MPP and International Diabetes Federation join forces to improve access to diabetes medicines","author":"Medicines Patent Pool","year":"2024"},{"issue":"1","key":"pmed.1004559.ref014","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12902-022-01026-2","article-title":"Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER","volume":"22","author":"SV Arnold","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"12","key":"pmed.1004559.ref015","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S2213-8587(21)00240-0","article-title":"Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis","volume":"9","author":"Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10400","key":"pmed.1004559.ref016","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"JP Frias","year":"2023","journal-title":"Lancet"},{"key":"pmed.1004559.ref017","doi-asserted-by":"crossref","first-page":"987081","DOI":"10.3389\/fendo.2022.987081","article-title":"Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China","volume":"13","author":"C Li","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"pmed.1004559.ref018","article-title":"Letter to 2023 WHO Expert Committee on the Selection & Use of Essential Medicines","author":"S Garimella","year":"2023","journal-title":"Geneva: WHO"},{"issue":"1","key":"pmed.1004559.ref019","doi-asserted-by":"crossref","first-page":"19351","DOI":"10.1038\/s41598-019-55524-w","article-title":"Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis","volume":"9","author":"M Castellana","year":"2019","journal-title":"Sci Rep"},{"issue":"10","key":"pmed.1004559.ref020","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/dom.14108","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"22","author":"C Mantsiou","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"pmed.1004559.ref021","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/dom.14130","article-title":"Features of oral glucose tolerance tests in patients after Roux-en-Y gastric bypass with and without hypoglycaemia symptoms in daily life: it\u2019s all about speed","volume":"22","author":"I Mari\u00ebn","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"pmed.1004559.ref022","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1111\/jdi.13531","article-title":"Efficacy of lifestyle intervention program for Arab women with prediabetes using social media as an alternative platform of delivery","volume":"12","author":"R Al-Hamdan","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"10","key":"pmed.1004559.ref023","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"J Rosenstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"pmed.1004559.ref024","doi-asserted-by":"crossref","first-page":"107927","DOI":"10.1016\/j.diabres.2019.107927","article-title":"Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: a systematic review and meta-analysis of randomized controlled trials","volume":"158","author":"D Patoulias","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"pmed.1004559.ref025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/oby.23331","article-title":"SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials","volume":"30","author":"AJY Cheong","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"pmed.1004559.ref026","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12020-019-02175-6","article-title":"The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis","volume":"67","author":"M Guo","year":"2020","journal-title":"Endocrine"},{"issue":"2","key":"pmed.1004559.ref027","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/dom.13531","article-title":"Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors","volume":"21","author":"CV Dave","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"pmed.1004559.ref028","article-title":"Multimorbidity, polypharmacy, severe hypoglycemia, and glycemic control in patients using glucose-lowering drugs for type 2 diabetes","author":"R Koto","year":"2023;14:1175-1192","journal-title":"Diabetes Ther"},{"issue":"13","key":"pmed.1004559.ref029","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2217\/cer-2021-0059","article-title":"Review and estimation of disutility for joint health states of severe and nonsevere hypoglycemic events in diabetes","volume":"10","author":"X Xie","year":"2021","journal-title":"J Comp Eff Res"},{"issue":"1","key":"pmed.1004559.ref030","doi-asserted-by":"crossref","first-page":"e3082","DOI":"10.1002\/dmrr.3082","article-title":"GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis","volume":"35","author":"M Castellana","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"pmed.1004559.ref031","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/dom.12785","article-title":"Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"19","author":"H Tang","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"pmed.1004559.ref032","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-8587(17)30015-3","article-title":"Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys","volume":"5","author":"P Ueda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"pmed.1004559.ref033","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s10157-021-02136-2","article-title":"Incidence of end-stage renal disease and risk factors for progression of renal dysfunction in Japanese patients with type 2 diabetes: the Fukuoka Diabetes Registry","volume":"26","author":"M Iwase","year":"2022","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"pmed.1004559.ref034","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2337\/dc18-1485","article-title":"Cumulative risk of end-stage renal disease among patients with type 2 diabetes: a nationwide inception cohort study","volume":"42","author":"P Finne","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"pmed.1004559.ref035","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.2337\/diacare.21.7.1138","article-title":"Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993","volume":"21","author":"K Gu","year":"1998","journal-title":"Diabetes Care"},{"key":"pmed.1004559.ref036","article-title":"Global Health Cost Effectiveness Analysis Registry","author":"Center for Evaluation of Value and Risk in Health (CEVR)","year":"2019"},{"issue":"4","key":"pmed.1004559.ref037","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s13300-019-0627-1","article-title":"Pancreatitis incidence in the exenatide BID, exenatide QW, and exenatide QW suspension development programs: pooled analysis of 35 clinical trials","volume":"10","author":"ML Vetter","year":"2019","journal-title":"Diabetes Ther"},{"issue":"1","key":"pmed.1004559.ref038","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jcjd.2021.04.006","article-title":"Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis","volume":"46","author":"M Colacci","year":"2022","journal-title":"Can J Diabetes"},{"issue":"4","key":"pmed.1004559.ref039","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.hfc.2022.03.008","article-title":"Sodium glucose cotransporter 2 inhibitors, amputation risk, and fracture risk","volume":"18","author":"C Arnott","year":"2022","journal-title":"Heart Fail Clin"},{"key":"pmed.1004559.ref040","doi-asserted-by":"crossref","first-page":"108136","DOI":"10.1016\/j.diabres.2020.108136","article-title":"Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of five randomized controlled trials","volume":"163","author":"S Miyashita","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"pmed.1004559.ref041","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"SR Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pmed.1004559.ref042","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/003335491613100124","article-title":"Prevalence of diabetes and health-related quality of life among rural-to-urban Nong Zhuan Fei migrants in an urban area of northern China, 2013","volume":"131","author":"S Yan","year":"2016","journal-title":"Public Health Rep"},{"issue":"2","key":"pmed.1004559.ref043","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"V Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"pmed.1004559.ref044","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.diabres.2018.03.027","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes\u2014a systematic review","volume":"140","author":"K R\u00e5dholm","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"10365","key":"pmed.1004559.ref045","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"pmed.1004559.ref046","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1111\/dom.14397","article-title":"Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100","volume":"23","author":"A-S Alexopoulos","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"pmed.1004559.ref047","article-title":"Association between early changes in metabolic parameters and retinopathy risk: analysis from the SUSTAIN and PIONEER trials","volume":"45","author":"R Brown","year":"2022","journal-title":"Diabetes Care"},{"key":"pmed.1004559.ref048","article-title":"Oral semaglutide versus injectable GLP-1 receptor agonists: a systematic review and meta-analysis","author":"M Davies","year":"2021;12:1901-1918","journal-title":"Diabetes Ther"},{"issue":"10","key":"pmed.1004559.ref049","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1517\/14656566.2015.1052740","article-title":"Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice","volume":"16","author":"CF Artigas","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"pmed.1004559.ref050","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA Clinical Practice Guideline on pharmacological interventions for adults with obesity","volume":"163","author":"E Grunvald","year":"2022","journal-title":"Gastroenterology"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T17:24:55Z","timestamp":1744910695000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004559"}},"subtitle":[],"editor":[{"given":"Lee-Ling","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004559","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}